| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
|
Cancer Res
|
2001
|
4.05
|
|
2
|
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
|
J Natl Cancer Inst
|
2000
|
2.73
|
|
3
|
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
|
Cancer Res
|
1999
|
2.00
|
|
4
|
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.
|
J Clin Oncol
|
2001
|
1.70
|
|
5
|
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
|
Eur J Cancer
|
2001
|
1.65
|
|
6
|
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
|
Clin Cancer Res
|
1999
|
1.54
|
|
7
|
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
|
Br J Cancer
|
1998
|
1.51
|
|
8
|
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
|
J Clin Oncol
|
1999
|
1.48
|
|
9
|
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
|
Br J Cancer
|
1999
|
1.45
|
|
10
|
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
|
Clin Cancer Res
|
2001
|
1.29
|
|
11
|
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.
|
Anticancer Drugs
|
2001
|
1.22
|
|
12
|
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.
|
Cancer Res
|
2000
|
1.21
|
|
13
|
Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
|
Drug Metab Dispos
|
2001
|
1.20
|
|
14
|
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
|
Anticancer Drugs
|
2001
|
1.16
|
|
15
|
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.
|
Ann Oncol
|
2010
|
1.14
|
|
16
|
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
|
Clin Cancer Res
|
1999
|
1.12
|
|
17
|
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
|
Clin Pharmacokinet
|
2001
|
1.12
|
|
18
|
Phase I and pharmacokinetic study of oral paclitaxel.
|
J Clin Oncol
|
2000
|
1.12
|
|
19
|
Co-administration of cyclosporin enables oral therapy with paclitaxel.
|
Lancet
|
1998
|
1.06
|
|
20
|
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.
|
Br J Cancer
|
2012
|
1.06
|
|
21
|
Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.
|
Clin Cancer Res
|
1997
|
1.01
|
|
22
|
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
|
Cancer Chemother Pharmacol
|
1998
|
1.01
|
|
23
|
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
|
Br J Cancer
|
2001
|
0.99
|
|
24
|
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
|
Br J Cancer
|
1997
|
0.98
|
|
25
|
Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
|
J Clin Oncol
|
1999
|
0.97
|
|
26
|
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
|
Clin Cancer Res
|
2000
|
0.96
|
|
27
|
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
|
J Clin Oncol
|
1997
|
0.96
|
|
28
|
Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.
|
Ann Oncol
|
2009
|
0.96
|
|
29
|
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
|
Br J Cancer
|
2001
|
0.96
|
|
30
|
Pharmacokinetically guided administration of chemotherapeutic agents.
|
Clin Pharmacokinet
|
2000
|
0.95
|
|
31
|
P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.
|
Pharmacol Res
|
1999
|
0.94
|
|
32
|
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.
|
Cancer Chemother Pharmacol
|
2000
|
0.93
|
|
33
|
Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.
|
J Clin Oncol
|
1997
|
0.93
|
|
34
|
Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
|
Clin Cancer Res
|
2000
|
0.92
|
|
35
|
The clinical pharmacology of alkylating agents in high-dose chemotherapy.
|
Anticancer Drugs
|
2000
|
0.92
|
|
36
|
The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.
|
Anticancer Drugs
|
2001
|
0.91
|
|
37
|
32P-postlabeling assay for the quantification of the major platinum-DNA adducts.
|
Anal Biochem
|
1999
|
0.91
|
|
38
|
Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.
|
Br J Clin Pharmacol
|
2000
|
0.91
|
|
39
|
Clinical research on antiangiogenic therapy.
|
Pharmacol Res
|
1998
|
0.90
|
|
40
|
Oral delivery of taxanes.
|
Invest New Drugs
|
2001
|
0.90
|
|
41
|
Cisplatin resistance and DNA repair.
|
Cancer Treat Rev
|
1998
|
0.90
|
|
42
|
A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
|
Cancer Chemother Pharmacol
|
2001
|
0.90
|
|
43
|
Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
|
Clin Pharmacol Ther
|
2000
|
0.90
|
|
44
|
Weekly high-dose cisplatin in malignant pleural mesothelioma.
|
Ann Oncol
|
1994
|
0.89
|
|
45
|
Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine.
|
J Chromatogr B Biomed Appl
|
1996
|
0.89
|
|
46
|
Cyclosporine-induced anaphylaxis.
|
Ann Pharmacother
|
2001
|
0.88
|
|
47
|
Clinical pharmacology of anticancer agents in relation to formulations and administration routes.
|
Cancer Treat Rev
|
1999
|
0.87
|
|
48
|
Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
|
Cancer Chemother Pharmacol
|
1995
|
0.87
|
|
49
|
Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1.
|
Cancer Chemother Pharmacol
|
1998
|
0.86
|
|
50
|
Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
|
Pharm World Sci
|
1998
|
0.86
|
|
51
|
Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry.
|
Fresenius J Anal Chem
|
2000
|
0.86
|
|
52
|
High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma.
|
J Chromatogr B Biomed Sci Appl
|
2001
|
0.86
|
|
53
|
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
|
Clin Cancer Res
|
1998
|
0.86
|
|
54
|
Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration.
|
Anticancer Drugs
|
2000
|
0.86
|
|
55
|
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
|
Eur J Cancer
|
1998
|
0.86
|
|
56
|
Progress in the development of alternative pharmaceutical formulations of taxanes.
|
Invest New Drugs
|
2001
|
0.85
|
|
57
|
A 'cocktail' strategy to assess in vivo oxidative drug metabolism in humans.
|
Trends Pharmacol Sci
|
1990
|
0.85
|
|
58
|
Oral topotecan: bioavailablity and effect of food co-administration.
|
Br J Cancer
|
1999
|
0.84
|
|
59
|
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.
|
Ann Oncol
|
1995
|
0.84
|
|
60
|
Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations.
|
Cancer Chemother Pharmacol
|
1996
|
0.84
|
|
61
|
Pharmaceutical development of anticancer agents derived from marine sources.
|
Anticancer Drugs
|
2000
|
0.84
|
|
62
|
Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
|
Pharmacol Res
|
1999
|
0.84
|
|
63
|
Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes.
|
Cancer Chemother Pharmacol
|
1996
|
0.83
|
|
64
|
The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.
|
Invest New Drugs
|
2000
|
0.83
|
|
65
|
Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
|
Br J Cancer
|
1995
|
0.82
|
|
66
|
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
|
J Clin Oncol
|
1996
|
0.82
|
|
67
|
Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F.
|
Anticancer Drugs
|
2001
|
0.82
|
|
68
|
Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure.
|
Cancer Chemother Pharmacol
|
2001
|
0.81
|
|
69
|
Antineoplastic agents. Drug interactions of clinical significance.
|
Drug Saf
|
1995
|
0.81
|
|
70
|
Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.
|
Br J Cancer
|
1994
|
0.81
|
|
71
|
The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor.
|
J Neurooncol
|
1998
|
0.81
|
|
72
|
Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.
|
Br J Clin Pharmacol
|
2001
|
0.80
|
|
73
|
Improved 32P-postlabelling assay for the quantification of the major platinum-DNA adducts.
|
Carcinogenesis
|
1997
|
0.80
|
|
74
|
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel.
|
Anticancer Drugs
|
2001
|
0.80
|
|
75
|
UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial.
|
Eur J Cancer
|
2001
|
0.80
|
|
76
|
In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide.
|
Cancer Treat Rev
|
1998
|
0.80
|
|
77
|
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
|
Br J Cancer
|
1998
|
0.79
|
|
78
|
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
|
Cancer Chemother Pharmacol
|
1996
|
0.79
|
|
79
|
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
|
Br J Cancer
|
1996
|
0.79
|
|
80
|
The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration.
|
J Neurooncol
|
1999
|
0.78
|
|
81
|
Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
|
J Clin Oncol
|
1999
|
0.78
|
|
82
|
Bleomycin.
|
Cancer Chemother Biol Response Modif
|
1996
|
0.78
|
|
83
|
Topoisomerase I inhibition: a new target or new missiles?
|
Ann Oncol
|
1995
|
0.78
|
|
84
|
Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods.
|
J Chromatogr B Biomed Sci Appl
|
1999
|
0.78
|
|
85
|
Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.
|
Anticancer Drugs
|
2000
|
0.78
|
|
86
|
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma.
|
Eur J Cancer
|
1996
|
0.78
|
|
87
|
Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma.
|
Eur J Clin Pharmacol
|
2001
|
0.78
|
|
88
|
Variability in drug metabolism: importance of genetic constitution.
|
Pharm Weekbl Sci
|
1987
|
0.77
|
|
89
|
A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel.
|
J Cancer Res Clin Oncol
|
1999
|
0.77
|
|
90
|
Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry.
|
Fresenius J Anal Chem
|
2001
|
0.77
|
|
91
|
UFT and oral calcium folinate as first-line chemotherapy for metastatic gastric cancer.
|
Oncology (Williston Park)
|
1999
|
0.76
|
|
92
|
Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.
|
Anticancer Drugs
|
2001
|
0.75
|
|
93
|
Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography.
|
J Chromatogr B Biomed Sci Appl
|
2001
|
0.75
|
|
94
|
Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.
|
Br J Cancer
|
1996
|
0.75
|
|
95
|
Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study.
|
Ann Oncol
|
2000
|
0.75
|
|
96
|
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
|
Br J Cancer
|
1997
|
0.75
|
|
97
|
Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer.
|
Pharmacol Res
|
1998
|
0.75
|
|
98
|
Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.
|
Anticancer Drugs
|
2000
|
0.75
|
|
99
|
Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer.
|
Anticancer Drugs
|
1999
|
0.75
|
|
100
|
Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection.
|
J Chromatogr B Biomed Sci Appl
|
2001
|
0.75
|
|
101
|
Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
|
Semin Oncol
|
1998
|
0.75
|
|
102
|
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.
|
Anticancer Drugs
|
1999
|
0.75
|
|
103
|
Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas.
|
Eur J Cancer
|
1998
|
0.75
|
|
104
|
Limited sampling models for topotecan pharmacokinetics.
|
Ann Oncol
|
1994
|
0.75
|
|
105
|
[Chemotherapy in brain tumors].
|
Ned Tijdschr Geneeskd
|
1996
|
0.75
|
|
106
|
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
|
Cancer Chemother Pharmacol
|
1999
|
0.75
|
|
107
|
In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM.
|
Anticancer Drugs
|
1999
|
0.75
|
|
108
|
Analysis of nifedipine and its pyridine metabolite dehydronifedipine in blood and plasma: review and improved high-performance liquid chromatographic methodology.
|
J Pharm Biomed Anal
|
1991
|
0.75
|
|
109
|
Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.
|
Clin Drug Investig
|
1998
|
0.75
|
|
110
|
Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.
|
Anticancer Drugs
|
1998
|
0.75
|
|
111
|
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel.
|
Eur J Clin Pharmacol
|
2001
|
0.75
|
|
112
|
Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model.
|
J Cancer Res Clin Oncol
|
1996
|
0.75
|
|
113
|
Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection.
|
J Chromatogr B Biomed Sci Appl
|
1997
|
0.75
|
|
114
|
A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen.
|
Cancer Chemother Pharmacol
|
1999
|
0.75
|
|
115
|
Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature.
|
Cancer Chemother Pharmacol
|
2000
|
0.75
|
|
116
|
Nifedipine: variability in its kinetics and metabolism in man.
|
Pharmacol Ther
|
1989
|
0.75
|
|
117
|
A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
|
Cancer Chemother Pharmacol
|
2001
|
0.75
|